News Related to Bladder Cancers

Related coverage linked through entity extraction aliases.

FDA-Approved Drug AMD3100 May Enable Immunotherapy for Rare Liver Cancer

Feb 13, 2026

Researchers find that AMD3100, an existing FDA-approved drug, can reverse T-cell exclusion in fibrolamellar carcinoma, potentially allowing immunotherapy to fight the rare and fatal liver cancer that primarily affects children and young adults.

Existing Drug May Overcome Immunotherapy Resistance in Rare Liver Cancer

Feb 13, 2026

Study finds FDA-approved drug AMD3100 can mobilize immune T cells to attack fibrolamellar carcinoma, a rare liver cancer affecting children and young adults that has resisted immunotherapy treatment.